A biopharma company engaged Magnolia to develop a value story for an orphan-designated treatment for an auto-immune disorder that was in Phase III development. The company’s product had a novel mechanism of action in comparison to the existing agents in development and would be the first new agent for the disease in years.
A small technology company developed an AI-assisted platform that is used to improve accuracy of a CV diagnostic tool. The company asked Magnolia to gather payer feedback on clinical evidence for the platforms and provide insights on future coverage and reimbursement.
Download to see features of the new healthcare delivery model and value-based care payment system for oncology practices, administered by the Centers for Medicare and Medicaid Services (CMS).
To gather early perceptions of the EOM and understand how oncology practices evaluated participation decisions in the new model, Magnolia facilitated an advisory panel discussion with key opinion leaders.
Biopharmaceutical companies engaged Magnolia to help them understand the implications of the Inflation Reduction Act of 2022 and develop long-term strategic plans to adjust for the sweeping market changes it will cause.
A development-stage biopharma company engaged Magnolia to help put in place an overarching launch road map for a drug that had just received positive phase 3 data.
A biopharma company needed an inpatient coding analysis for their new medication.
A pharmaceutical company offering a hub designed to address patient medication access challenges received customer feedback expressing dissatisfaction from both patients and providers.
A biopharma company wanted to know the likelihood of receiving an NTAP after launching an inpatient treatment.
Download to see features of the proposed rule.